Cardiff Oncology (CRDF) announced the company has appointed Roger Sidhu as chief medical officer. Sidhu is a veteran executive and clinician with over 20 years of experience and a strong track record of success in oncology research, development, and regulatory strategy. Sidhu succeeds Fairooz Kabbinavar who will remain with the company in an advisory role. The company also announced it will share additional clinical data from its lead program in RAS-mutated mCRC on July 29. Sidhu was most recently the chief medical officer and acting CEO at Treadwell Therapeutics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDF:
- Cardiff Oncology’s Onvansertib: Anticipated Phase II Results and Market Potential Drive Buy Rating
- Cardiff Oncology ‘highly encouraged’ by onvansertib data presented at ASCO
- Cardiff Oncology’s Onvansertib: A Strategic Expansion into New Cancer Indications with Blockbuster Potential
- Cardiff Oncology Reports Increased Losses Amid Rising R&D Costs
- Cardiff Oncology price target raised to $18 from $17 at H.C. Wainwright